Beneficial ownership — 13D / 13G
87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | BBUC Brookfield Business Corp | 13G/A | 0.55% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | NGVT Ingevity Corp | 13G/A | 4.2% | Mar 31, 2026 | 6mo |
| First Trust Capital Management L.P. | SDHI Siddhi Acquisition Corp (Cayman Islands) | 13G/A | 4.67% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | OLB Olb Group, Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | VSEE Vsee Health, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Woodline Partners LP | OM Outset Medical, Inc. | 13G/A | 1.6% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | FOSL Fossil Group, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | JACK Jack In The Box Inc | 13G | 8.1% | Mar 31, 2026 | 6mo |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | WPP WPP plc | 13G | 7.59% | Mar 31, 2026 | 6mo |
| Balyasny Asset Management L.P. | LXEO Lexeo Therapeutics, Inc. | 13G/A | 9.69% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | MIDD MIDDLEBY Corp | 13G/A | 13.6% | Mar 31, 2026 | 6mo |
| Orbis Investment Management Limited | BUR Burford Capital Ltd | 13G/A | 8.5% | Mar 31, 2026 | 6mo |
| Redpoint Ventures V, L.P. | BTGO Bitgo Holdings, Inc. | 13G | 9.8% | Mar 31, 2026 | 6mo |
| PointState Capital LP | STUB StubHub Holdings, Inc. | 13G/A | 6.4% | Mar 31, 2026 | 6mo |
| Woodline Partners LP | OKYO OKYO Pharma Ltd | 13G | 7% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | PHVS Pharvaris N.V. | 13G/A | 5.6% | Mar 31, 2026 | 6mo |
| PARADIGM CAPITAL MANAGEMENT INC/NY | CRNC Cerence Inc. | 13G | 5.6% | Mar 31, 2026 | 6mo |
| JANUS HENDERSON GROUP PLC | LGVN Longeveron Inc. | 13G | 5.9% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | SNEX StoneX Group Inc. | 13G/A | 4.4% | Mar 31, 2026 | 6mo |
| Saba Capital Management, L.P. | RDAG Republic Digital Acquisition Co | 13G/A | 7.58% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | STTK Shattuck Labs, Inc. | 13G/A | 13.8% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | INBS Intelligent Bio Solutions Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | IEX Idex Corp | 13G/A | 2.3% | Mar 31, 2026 | 6mo |
| Durable Capital Partners LP | RBC RBC Bearings INC | 13G/A | 7.2% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | NP Neptune Insurance Holdings Inc. | 13G | 5% | Mar 31, 2026 | 6mo |
| CITADEL ADVISORS LLC | SNCY Sun Country Airlines Holdings, LLC | 13G/A | 2.5% | Mar 31, 2026 | 6mo |
| Caligan Partners LP | SABS SAB Biotherapeutics, Inc. | 13G | 10.4% | Mar 31, 2026 | 6mo |
| 12 West Capital Management LP | MRVI Maravai Lifesciences Holdings, Inc. | 13G/A | 4.9% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | BTAIQ BioXcel Therapeutics, Inc. | 13G | 7.05% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | AVTX Avalo Therapeutics, Inc. | 13G | 9.5% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | ATRC AtriCure, Inc. | 13G/A | 6.8% | Mar 31, 2026 | 6mo |
| Deep Track Capital, LP | TARS Tarsus Pharmaceuticals, Inc. | 13G/A | 8.46% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | CECO Ceco Environmental Corp | 13G | 6% | Mar 31, 2026 | 6mo |
| MPM BIOIMPACT LLC | FBRX Forte Biosciences, Inc. | 13G | 7.2% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | TSEM Tower Semiconductor Ltd | 13G | 6.6% | Mar 31, 2026 | 6mo |
| JANUS HENDERSON GROUP PLC | ASND Ascendis Pharma A/S | 13G/A | 6% | Mar 31, 2026 | 6mo |
| Cormorant Asset Management, LP | RLYB Rallybio Corp | 13G | 7.56% | Mar 31, 2026 | 6mo |
| CVI Investments, Inc. | EBON Ebang International Holdings Inc. | 13G/A | 2.4% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | GLBS Globus Maritime Ltd | 13G/A | 4.99% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | SPRB Spruce Biosciences, Inc. | 13G/A | 4.49% | Mar 31, 2026 | 6mo |
| Paradigm Biocapital Advisors LP | URGN UroGen Pharma Ltd. | 13G/A | 3.5% | Mar 31, 2026 | 6mo |
| Empyrean Capital Partners, LP | RAC Rithm Acquisition Corp. | 13G/A | 9.43% | Mar 31, 2026 | 6mo |
| Lytton, Laurence W. | TELA TELA Bio, Inc. | 13G/A | 5.5% | Mar 31, 2026 | 6mo |
| BIOTECHNOLOGY VALUE FUND L P | FDMT 4D Molecular Therapeutics, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| MMCAP International Inc. SPC | CRDL Cardiol Therapeutics Inc. | 13G/A | 17.9% | Mar 31, 2026 | 6mo |
| 1607 Capital Partners, LLC | TSI Tcw Strategic Income Fund Inc | 13G | 5.46% | Mar 31, 2026 | 6mo |
| METEORA CAPITAL, LLC | DYNC Dynamix Corp | 13G/A | 14.78% | Mar 31, 2026 | 6mo |
| AQR CAPITAL MANAGEMENT LLC | PB Prosperity Bancshares Inc | 13G | 6.23% | Mar 31, 2026 | 6mo |
| Kenneth Griffin | WULF Terawulf Inc. | 13G/A | 3.7% | Mar 31, 2026 | 6mo |
| Bastion Trading Limited | SKYA SkyAI, Inc. | 13G/A | 9.9% | Mar 31, 2026 | 6mo |